NewLink Genetics shares shoot higher after FDA Ebola vaccine approval
Streetwise Reports: Shares of NewLink Genetics got a boost today after the firm reported that the FDA approved its Ervebo V920 vaccine used in the treatment of Zaire Ebola virus. The Ames-based company’s shares set a new 52-week high price in midmorning trading. NewLink indicated that this represents the first vaccine approved by the FDA for the Ebola virus.
Trending News
